Mendus AB (publ) - Asset Resilience Ratio
Mendus AB (publ) (IMMU) has an Asset Resilience Ratio of 10.29% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Mendus AB (publ)'s equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Mendus AB (publ)'s Asset Resilience Ratio has changed over time. See Mendus AB (publ) (IMMU) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Mendus AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Mendus AB (publ).
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr64.66 Million | 10.29% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr64.66 Million | 10.29% |
Asset Resilience Insights
- Moderate Liquidity: Mendus AB (publ) has 10.29% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Mendus AB (publ) Industry Peers by Asset Resilience Ratio
Compare Mendus AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Mendus AB (publ) (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Mendus AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.29% | Skr64.66 Million ≈ $6.96 Million |
Skr628.32 Million ≈ $67.62 Million |
-4.34pp |
| 2024-12-31 | 14.63% | Skr101.91 Million ≈ $10.97 Million |
Skr696.36 Million ≈ $74.94 Million |
-1.34pp |
| 2023-12-31 | 15.98% | Skr120.78 Million ≈ $13.00 Million |
Skr755.95 Million ≈ $81.35 Million |
+9.23pp |
| 2022-12-31 | 6.75% | Skr41.85 Million ≈ $4.50 Million |
Skr620.39 Million ≈ $66.76 Million |
-14.80pp |
| 2021-12-31 | 21.54% | Skr155.31 Million ≈ $16.71 Million |
Skr720.98 Million ≈ $77.59 Million |
-1.47pp |
| 2020-12-31 | 23.01% | Skr167.64 Million ≈ $18.04 Million |
Skr728.66 Million ≈ $78.42 Million |
+18.53pp |
| 2019-12-31 | 4.47% | Skr13.59 Million ≈ $1.46 Million |
Skr303.83 Million ≈ $32.70 Million |
-94.27pp |
| 2018-12-31 | 98.74% | Skr444.70 Million ≈ $47.86 Million |
Skr450.37 Million ≈ $48.47 Million |
+46.61pp |
| 2017-12-31 | 52.13% | Skr128.32 Million ≈ $13.81 Million |
Skr246.15 Million ≈ $26.49 Million |
+44.29pp |
| 2016-12-31 | 7.84% | Skr9.53 Million ≈ $1.03 Million |
Skr121.57 Million ≈ $13.08 Million |
+1.68pp |
| 2015-12-31 | 6.15% | Skr9.49 Million ≈ $1.02 Million |
Skr154.24 Million ≈ $16.60 Million |
-43.72pp |
| 2014-12-31 | 49.87% | Skr35.43 Million ≈ $3.81 Million |
Skr71.03 Million ≈ $7.64 Million |
-- |
About Mendus AB (publ)
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The com… Read more